Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig 2. Disease-free and overall survival in (A, B) responding, (C, D) nonresponding, and (E, F) all patients comparing response-guided with conventional.

Published byLucas Gabriel Lucas Galindo Modified over 4 years ago

Similar presentations

Presentation on theme: "Fig 2. Disease-free and overall survival in (A, B) responding, (C, D) nonresponding, and (E, F) all patients comparing response-guided with conventional."— Presentation transcript:

1 Fig 2. Disease-free and overall survival in (A, B) responding, (C, D) nonresponding, and (E, F) all patients comparing response-guided with conventional chemotherapy. NX, vinorelbine and capecitabine; TAC, docetaxel, doxorubicin, and cyclophosphamide. Published in: Gunter von Minckwitz; Jens Uwe Blohmer; Serban Dan Costa; Carsten Denkert; Holger Eidtmann; Wolfgang Eiermann; Bernd Gerber; Claus Hanusch; Jörn Hilfrich; Jens Huober; Christian Jackisch; Manfred Kaufmann; Sherko Kümmel; Stefan Paepke; Andreas Schneeweiss; Michael Untch; Dirk Michael Zahm; Keyur Mehta; Sibylle Loibl; Journal of Clinical Oncology  DOI: /JCO Copyright © 2013

Download ppt "Fig 2. Disease-free and overall survival in (A, B) responding, (C, D) nonresponding, and (E, F) all patients comparing response-guided with conventional."

Similar presentations

Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple.

Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple.
OPEN ISSUES IN MULTIDISCIPLINARY BREAST CANCER MANAGEMENT

OPEN ISSUES IN MULTIDISCIPLINARY BREAST CANCER MANAGEMENT
The phase III ICE study: Adjudiscloseant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer Gunter.

The phase III ICE study: Adjudiscloseant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer Gunter.
Taxanes — Taxanes are among the most active agents for metastatic breast cancer – Docetaxel, Paclitaxel, NabPaclitaxel. Anthracyclines – Doxorubicin, Epirubicin,

Taxanes — Taxanes are among the most active agents for metastatic breast cancer – Docetaxel, Paclitaxel, NabPaclitaxel. Anthracyclines – Doxorubicin, Epirubicin,
Response-Guided Neoadjuvant Chemotherapy for Breast Cancer Gunter von Minckwitz, Jens Uwe Blohmer, Serban Dan Costa, Carsten Denkert, Holger Eidtmann Journal.

Response-Guided Neoadjuvant Chemotherapy for Breast Cancer Gunter von Minckwitz, Jens Uwe Blohmer, Serban Dan Costa, Carsten Denkert, Holger Eidtmann Journal.
2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages 332-384 (March.

2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages 179-202 (January 2016) DOI: 10.1016/j.jhep.2015.07.040.

EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.

Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.
Volume 34, Pages 122-130 (August 2017) Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer – Results from the.

Volume 34, Pages (August 2017) Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer – Results from the.
A. Schema of NSABP B-27 trial comparing neoadjuvant AC to neoadjuvant AC followed by neoadjuvant docetaxel and to neoadjuvant AC followed by adjuvant docetaxel.

A. Schema of NSABP B-27 trial comparing neoadjuvant AC to neoadjuvant AC followed by neoadjuvant docetaxel and to neoadjuvant AC followed by adjuvant docetaxel.
Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial)  M. Yoshida, K. Muro, A. Tsuji,

Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial)  M. Yoshida, K. Muro, A. Tsuji,
The clinical features and management of women with ductal carcinoma in situ with microinvasion: A retrospective Cohort study  Ying Li, Sheng Zhang, Xi.

The clinical features and management of women with ductal carcinoma in situ with microinvasion: A retrospective Cohort study  Ying Li, Sheng Zhang, Xi.
The effect of perioperative chemotherapy for patients with an adenocarcinoma of the gastroesophageal junction: A propensity score matched analysis  K.

The effect of perioperative chemotherapy for patients with an adenocarcinoma of the gastroesophageal junction: A propensity score matched analysis  K.
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.

Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.
Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.

Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.
Oral Vinorelbine and Cisplatin with Concurrent Radiotherapy After Induction Chemotherapy with Cisplatin and Docetaxel for Patients with Locally Advanced.

Oral Vinorelbine and Cisplatin with Concurrent Radiotherapy After Induction Chemotherapy with Cisplatin and Docetaxel for Patients with Locally Advanced.
Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from.

Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from.
A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing  Klazien Matter-Walstra, PhD, Matthias.

A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing  Klazien Matter-Walstra, PhD, Matthias.
Anxiety After Diagnosis Predicts Lung Cancer–Specific and Overall Survival in Patients With Stage III Non–Small Cell Lung Cancer: A Population-Based Cohort.

Anxiety After Diagnosis Predicts Lung Cancer–Specific and Overall Survival in Patients With Stage III Non–Small Cell Lung Cancer: A Population-Based Cohort.
Khaled M. Madbouly, Abdrabou N. Mashhour, Waleed Omar 

Khaled M. Madbouly, Abdrabou N. Mashhour, Waleed Omar 

Similar presentations

Ads by Google